miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3...

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The molecular mechanisms driving lung cancer drug resistance remain largely unknown.
• Endoplasmic reticulum stress mediator CHOP (DNA damage inducible transcript 3) is implicated in apoptosis but its role in solid tumor multidrug resistance is unclear.

Purpose of the Study:

• To investigate the role of CHOP in lung cancer multidrug resistance.
• To identify molecular regulators of CHOP expression in lung cancer.

Main Methods:

• Analysis of CHOP expression in lung cancer patient tumor tissues.
• In vitro experiments involving silencing or augmenting CHOP expression in cisplatin-resistant and sensitive lung cancer cells.
• Investigation of CHOP's regulatory targets, including autophagy and apoptosis-related genes (LC3-II, DR5, TERF3).
• Assessment of miR-146a's role in regulating CHOP expression and its impact on chemotherapy sensitivity using animal models.

Main Results:

• Deficient CHOP expression in lung cancer patients correlates with poor prognosis.
• Cisplatin-resistant lung cancer cells show reduced CHOP expression.
• CHOP modulates cisplatin resistance by regulating LC3-II, DR5, and TERF3.
• miR-146a directly targets CHOP mRNA, leading to its down-regulation.
• Abnormal miR-146a expression alters chemotherapy sensitivity in lung cancer without affecting tumor growth.

Conclusions:

• CHOP serves as a prognostic biomarker for lung cancer.
• miR-146a represents a potential therapeutic target for overcoming multidrug resistance in lung cancer.